SlideShare a Scribd company logo
LOW GRADE GLIOMA PANEL
5/5/2023 1
DR L N TRIPATHY
Senior Vice Chairman, Director
Senior Consultant, Neurosurgery
Medica Super specialty Hospital, Kolkata
ISNOCON 2023- KOLKATA
DR KANHU CHARAN PATRO
HOD, Radiation Oncology
Mahatma Gandhi Cancer Hospital & RI
Visakhapatnam
Dr
ADHITHYAN
Dr Amit
Kumar Ghosh
Dr Anila
Sharma
DR Nilesh
Mahale
Dr Vikas Jagtap
Dr Devleena
Gangopadhya
Definition
The term diffuse infiltrating means there is no
identifiable border between the tumour and
normal brain tissue, even though the borders
may appear well-marginated on imaging
5/5/2023 11
Some facts
• Diffuse astrocytomas, also referred to as low-grade infiltrative
astrocytomas, are designated as WHO II tumours of the brain.
• Commonly, astrocytomas are confined to white matter although they
can infiltrate and expand the adjacent cortex in later stages.
• However, oligodendroglioma is frequently a cortical-based tumor.
• Although contrast enhancement has been classically associated
with a higher degree of malignancy, contrast enhancement may be
seen in up to 20% of LGG
5/5/2023 12
Case details
39-year male
• P/w –frontal headache
• Personality changes- 6 month
• Single episode of generalized seizure
• Disturbance with selective attention
MRI
• LT. temporal lesion
• 6cm in greatest dimension
• Solid cystic pattern
• No enhancement
• Midline shift
• Mass effect
• Ventricular effacement
Dr ADHITHYAN PLEASE
IMAGING PROTOCOL
RADIOLOGY
• PRESCRIPTION
• MRS,DIFFUSION,PERFUSION
• TRACTOGRAPHY
• RADIOMICS AND
RADIOGENOMICS
T1
T1-
Contrast
T2
T2 Flair
Perfusion
Perfusion
SWI
DWI-ADC
5/5/2023 23
MRS
5/5/2023 25
2HG MRS
5/5/2023 26
IDH MUTATION
IDH WILD
using 2 mM 2HG as threshold to discriminate IDH-mutated from wildtype tumors
T2-FLAIR
mismatch sign
GRADE II OLIGO
[BLOOMING]
DR AMIT PLEASE
SURGERY DETAILS
How will
you
proceed?
Observation?
Surgery
Which type of surgery
Surgical procedure
NEUROSURGERY
• What type surgery
• Eloquent location
• Stereotactic biopsy
• Imaging after surgery
• Awake craniotomy
Surgery recommendation
• It is assumed that surgery should aim for the greater extent of resection as it
would Increase survival and potentially alter the natural history of the disease:
gross total removal or subtotal tumor removal (when feasible and safe) is
superior to biopsy in terms of decreasing the rate of tumor progression and also
have positive impact in overall survival estimation of resection less than 50%
would lead to consider biopsy.
• A retrospective multicentric study analyzing 1097 patients (in which the
assessed population was divided into three subgroups depending on the extent
of resection: 100%, 50–99% and less than 50%) showed that the amount of
residual lesion impacted on the course of the disease (OS was 10.5 and 14
years for patients with a less than 50 and 50–99% Extent of resection, being
unreached instead after 15 years for patients with no residual tumor).
• Biopsy is indicated when diagnosis is needed in deep lesions (including
brainstem), diffuse and/or multicentric tumor or any other contraindication for
open resection.
• Biopsy can be stereotactic (framed or frameless) or open. Neuronavigated
non-framed biopsy is gaining acceptance.
5/5/2023 32
SURGERY
• PATIENT UNDERWENT SURGERY
• COMPLETE EXCISION
• BETTER AFTER SURGERY
5/5/2023 33
Dr ADHITHYAN PLEASE
POST OP IMAGING PROTOCOL
TIMING OF POST OP MRI
5/5/2023 35
5/5/2023 36
5/5/2023 37
NEUROPATHOLOGY
• Classification
• Histopathology
• IHC
• Molecular profile
DR ANILA PLEASE
H/P GUIDENCE
Brain tumor diagnosis
Next generation
sequence
[NGS]
Methylation profiling
Immunohistochemistry
[IHC]
Microscopic
Histology
40
Layered reporting in brain tumors
Thus, to display the full range of diagnostic information available, the use of
layered (or tiered) diagnostic reports is strongly encouraged, as endorsed by
the International Society of Neuropathology—Haarlem consensus
guidelines and the International Collaboration on Cancer Reporting.
Layered diagnosis
5/5/2023 42
H/ P REPORT
• DIFFUSE GLIOMA
• GRADE ll
5/5/2023 43
1. Nuclear irregularities with fibrillary processes
are diagnosed as astrocytoma
2. Infiltrative, diffuse growth pattern with the
formation of secondary structures of Scherer
Moderately cellular
3. Irregular cell distribution
4. Nuclear atypia is typical, yet variable: enlarged
elongated hyperchromatic irregular nuclei
5. Variable amount of cytoplasm: may be scant
(naked nuclei) to moderate with processes
creating a fibrillary background
6. No mitotic activity (a single mitosis in a
sizable specimen is allowed)
7. No necrosis or microvascular proliferation
8. Variable microcystic change
9. Variable calcification
Oligodendroglioma
5/5/2023 44
Micrograph of an oligodendroglioma showing the characteristic branching,
small, chicken wire-like blood vessels and fried egg-like cells, with clear cytoplasm
and well-defined cell borders. H&E stain. Those with uniformly rounded nuclei and
perinuclear halo (‘‘fried egg’’) are considered oligodendrogliomas.
Atypia
Mitosis
Endothelial
Proliferation
Necrosis
AMEN SCORE
45
Defining and grading of IDH mutant and IDH wild
46
Adult diffuse gliomas – current status
Two deciding factors
5/5/2023 49
IDH MUTATION AND GLIOMA-GENESIS
5/5/2023 50
Mixed entity
5/5/2023 51
Diffuse glioma
Oligodendro glioma
IDH mutant
1p19q co-deleted
Glioblastoma
IDH wild
Diffuse glioma
IDH mutant
52
Diffuse glioma
Oligodendro glioma
IDH mutant
1p19q co-deleted
IDH wild
Glioblastoma
Diffuse glioma
IDH mutant
53
Grade-2
Grade-3
Grade-4
Grade-2
Grade-3
When will we call as glioblastoma?
• Diffuse astrocytoma IDH wild type with
• TERT promoter mutation
• Necrosis
• Microvascular proliferation
• EGFR gene amplification
• Combined entire gain of chromosome 7 and
entire loss of chromosome 10[+7/-10]
55
Revised schema of classification: post WHO CNS5
NIMHANS WEBSITE
FINAL REPORT
• DIFFUSE GLIOMA
• IDH MUTANT
• 1P/19q CO DELETION
• OLIGODENDDROGLIOMA
• GRADE ll
DR NILESH PLEASE
ADJUVANT TREATMENT
ADJUVANT
TREATMENT
Observation
Radiation
Conc. Chemo
Adjuvant chemo
5/5/2023 63
Options
• RT alone
• RT- adj. PCV
• RT- adj. TMZ
• RT- conc. And adj. TMZ - 6
• RT- conc. And adj. TMZ - 12
5/5/2023 64
Planning for
observation
• Besides IDH wild-type status, other high-risk factors
include
– Age > 40 years,
– Subtotal resection/biopsy only,
– Astrocytic lineage (lack of 1p/19q codeletion),
– Neurologic deficits prior to surgery,
– Tumor diameter > 6 cm, tumor crossing the
midline of the brain,
– tumors located within or adjacent to eloquent
areas of the brain
• Patients without these risk factors can be considered at
low risk; therefore, after gross total resection, they
should be observed closely with surveillance MRI every
3 months initially, and if there is no demonstrated tumor
growth over a 1-year period, then the imaging interval
can be increased to every 4 months for another year,
and eventually every 6 months for the remainder of the
patient’s life
5/5/2023 65
Why not now?
5/5/2023 67
DR VIKAS PLEASE
DOSE AND TECHNIQUE
RADIOTHERAPY
PLANNIG IMAGE
DOSE
TARGET DELINEATION
TECHNIQUE
5/5/2023 70
Technique and dose
GTV- CTV- PTV PARAMETERS
Case study
Post op images
Contouring details
DR DEVLEENA PLEASE
ABOUT CONC. AND ADJUVANT CHEMO
CHEMOTHERAPY
CONC. CHEMO
ADJUVANT CHEMO
Concurrent chemo
TEMOZOLOMIDE
VS
NO TEMOZOLOMIDE
Concurrent CTRT trial
5/5/2023 81
TRIAL INCLUSION ARM RESULT
RTOG 0424 LGG with >3 risk
factors for
recurrence (age >
40 years,
astrocytoma
histology,
bihemispheric
tumor, tumor
diameter[6 cm,
neurologic
function status
Concurrent
radiation
(54 Gy) with
TMZ f/b
monthly TMZ
1. The 3-year OS rate was 73% (95% CI
65.3–80.8%), significantly higher
than the historical control OS rate of
54% (p0.001).
2. The 5-year OS rate was 57.1% (95%
CI 47.7–66.5%), and the median OS
has not yet been reached.
3. The 3-year PFS was 59.2% (95% CI
50.7–67.8%) and median PFS was
4.5 years (95% CI 3.5–NA).
Fisher BJ. J Radiat Oncol Biol Phys.(2015)
For anaplastic astrocytoma IDHmt, the interim results of the CATNON trials strongly
suggest treatment with 59.4Gy radiotherapy in fractions of 1.8Gy followed by 12 cycles of
adjuvant temozolomide chemotherapy (200mg/m2 days 1–5 in a 4-week cycle
CODEL
Adjuvant chemo
• After radiation, patient received adjuvant PCV
(procarbazine, CCNU, and vincristine) due to 1p/19q
co-deletion (per RTOG 9802).
PCV trial
5/5/2023 86
TRIAL INCLUSION ARM RESULT
RTOG 9802 1. Age >40 years
and/or subtotal
resection
RT (54 Gy)
VS
RT (54 Gy)
And 6 cycles
of adjuvant
PCV
1. Post-RT + PCV conferring a survival
advantage over RT alone: median OS
13.3 versus 7.8 years (HR: 0.59; 95%
CI 0.42–0.83; p = 0.003).
2. Median PFS was prolonged in
patients who received PCV (10.4
versus 4.0 years): HR: 0.50; 95% CI
0.36–0.68 (p0.001)
Buckner JC. N Engl J Med(2016)
Follow up
MUTATED
WILD
EXTRA SLIDES
Radiotherapy trials
5/5/2023 90
TRIAL INCLUSION ARM RESULT
EORTC 22844 1. Low-grade
astrocytomas
Low dose RT
(45 Gy)
VS
High dose RT
(59.4 Gy)
1. No significant difference in the 5-
years OS between low-dose arm
(58%) and high dose arm (59%).
2. No significant difference in the 5-
years PFS (47% verss 50%)
Karim AB. Int J Radiat Oncol Biol Phys
1996
Radiotherapy trials
5/5/2023 91
TRIAL INCLUSION ARM RESULT
EORTC 22845
Interim
1. Low-grade
astrocytoma
Early RT
(54 Gy)
VS
No RT
1. Early RT showed an improvement in
TTP (4.8 versus 3.4 years; p = 0.02).
HR = 0.68 (95% CI 0.50–0.94).
2. No differences in OS: HR = 1.15 (95%
CI 0.67–1.74).
3. The 5-year OS rate were: 63 versus
66% (p = 0.49).
(Karim AB. Int J Radiat Oncol Biol
Phys(2002)
Radiotherapy trials
5/5/2023 92
TRIAL INCLUSION ARM RESULT
EORTC 22845 1. WHO grade II RT (54 Gy)
after biopsy
resection,
VS
No RT until
progression
1. Early RT was associated with an
improvement PFS (5.3 versus 3.4
years): HR = 0.59; 95% CI 0.45–0.77
(p = 0.0001).
2. No difference in OS (7.4 versus 7.2
years): HR = 0.97; 95% CI 0.71–1.34
8 (p = 0.872)
3. Seizure control also improved in
patients treated with early
radiotherapy.
Van den Bent MJ. Lancet
2005)
Radiotherapy trials
5/5/2023 93
TRIAL INCLUSION ARM RESULT
NCCTG/RTOG/
ECOG
1. WHO grade II
gliomas
Low dose RT
(50.4 Gy)
VS
High dose RT
(64.8 Gy)
1. No differences in 2- and 5-year OS
between low dose (94 and 75%) and
high dose arm (85 and 64%) (p =
0.48)
2. Patients treated with high doses
showed higher rates of severe
radionecrosis (5 versus 2.5%)
Shaw EG. J Clin Oncol.
(2002)
Radiotherapy trials
5/5/2023 94
TRIAL INCLUSION ARM RESULT
RTOG 0424 LGG with >3 risk
factors for
recurrence (age >
40 years,
astrocytoma
histology,
bihemispheric
tumor, tumor
diameter[6 cm,
neurologic
function status
Concurrent
radiation
(54 Gy) with
TMZ f/b
monthly TMZ
1. The 3-year OS rate was 73% (95% CI
65.3–80.8%), significantly higher
than the historical control OS rate of
54% (p0.001).
2. The 5-year OS rate was 57.1% (95%
CI 47.7–66.5%), and the median OS
has not yet been reached.
3. The 3-year PFS was 59.2% (95% CI
50.7–67.8%) and median PFS was
4.5 years (95% CI 3.5–NA).
Fisher BJ. J Radiat Oncol Biol
Radiotherapy trials
5/5/2023 95
TRIAL INCLUSION ARM RESULT
EORTC 22033 LGG with at least
one high-risk
feature (aged>40
years,
progressive
disease, tumour
Size>5 cm, tumour
crossing the
midline, or
neurological
symptoms)
RT ( 50.4 Gy
VERSUS
Dose-dense
oral TMZ
(75 mg/m2
once daily for
21 days,
every
28 days, for a
maximum
of 12 cycles)
1. There was no significant difference
in PFS between TMZ group (39
months) and RT group (46 months):
HR: 1.16; 95% CI 0.9–1.5 (p = 0.22).
2. Median OS has not been reached.
3. Better PFS in IDH-mutant
noncodeleted patients treated with
radiotherapy: 55 versus 36 months.
HR 1.86; 95% CI 1.21–2.87 (p =
0.0043)
Baumert BG Lancet Oncol.
Radiotherapy trials
5/5/2023 96
TRIAL INCLUSION ARM RESULT
Wahl M,et al LGG and gross
residual disease
Monthly
cycles of TMZ
for up to 1
year or until
disease
progression
1. The median PFS and OS were 4.2
and 9.7 years, respectively.
2. Patients with 1p/19q codeletion
demonstrated a 0% risk of
progression during treatment
Neuro
Oncol.(2017)
Recommendation -1
• People with oligodendroglioma, IDH-mutant, 1p19q codeleted, CNS WHO
grade 2 should be offered radiation in combination with PCV
• TMZ is a reasonable alternative to PCV when toxicity is a concern
5/5/2023 97
Recommendation -2
• People with oligodendroglioma, IDH-mutant, 1p19q codeleted, CNS WHO
grade 2, initial therapy may be deferred until radiographic or symptomatic
progression in some people with positive prognostic factors (eg, complete
resection and younger age) or concerns about toxicity
Recommendation -3
• People with oligodendroglioma, IDH-mutant, 1p19q codeleted, CNS WHO
grade 3 should be offered radiation in combination with PCV
• TMZ is a reasonable alternative to PCV when toxicity is a concern
GRADE 3 IDH MUTANT AND CODELETED TUMORS
Recommendation -4
• People with Astrocyoma, IDH-mutant, 1p19q NONcodeleted, CNS WHO
grade 2 should be offered radiation in combination with PCV
• TMZ is a reasonable alternative to PCV when toxicity is a concern
GRADE 2 IDH MUTANT AND NON-CODELETED TUMORS
Recommendation -5
• People with Astrocytoma, IDH-mutant, 1p19q NONcodeleted, CNS WHO
grade 2, initial therapy may be deferred until radiographic or symptomatic
progression in some people with positive prognostic factors (eg, complete
resection and younger age) or concerns about toxicity
Recommendation -6
• People with astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO
grade 3 should be offered RT with adjuvant TMZ
Recommendation -7
• People with astrocytoma, IDH mutant CNS WHO grade 4 may be treated like an
astrocytoma, IDH-mutant, non-codeleted, CNS WHO grade 3 (formerly anaplastic
astrocytoma; see Recommendation 6) or like a glioblastoma, IDH-wildtype, CNS WHO
grade 4
Recommendation - 8
• People with astrocytomas, IDH-wildtype, CNS WHO grade 2 or 3 may be
treated according to recommendations for glioblastoma
Recommendation -9
• Concurrent TMZ and RT should be offered to people with newly diagnosed
glioblastoma, IDH-wildtype, CNS WHO grade 4
Recommendation -10
• Six months of adjuvant TMZ should be offered to people with newly diagnosed
glioblastoma, IDH-wildtype, CNS WHO grade 4 who have received concurrent
RT plus TMZ
Recommendation -11
• Alternating electric field therapy may be added to adjuvant TMZ in people with
newly diagnosed supratentorial glioblastoma, IDH-wildtype, CNS WHO grade 4
who have completed chemoradiation therapy
Recommendation -12
• Bevacizumab is not recommended for people with newly diagnosed
glioblastoma, IDH-wildtype, CNS WHO grade 4
Bevacizumab is not recommended for people with newly
diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4
Benefits do not outweigh harms
Recommendation -13
• In people with glioblastoma, IDH-wildtype, CNS WHO grade 4 where the expected survival
benefits of a 6-week radiation course combined with TMZ may not outweigh the harms,
hypofractionated RT combined with TMZ is a reasonable alternative
Recommendation -14
• In people with glioblastoma, IDH-wildtype, CNSWHO grade 4 with older age, poor
performance status or with concerns about toxicity or prognosis, best supportive care
alone, hypofractionated RT alone (for MGMT promoter unmethylated tumors) or TMZ
alone (for MGMT promoter methylated tumors) are reasonable options.
Recommendation -15
• No recommendation for or against any therapeutic strategy can be made for
treatment of recurrent glioblastoma, IDH wildtype, CNS WHO grade 4
• People with recurrent glioblastoma should be referred for participation in a
clinical trial where possible
Recommendation -16
• No recommendation for or against any therapeutic strategy can be made for
treatment of diffuse midline glioma
• People with diffuse midline glioma should be referred for participation in a
clinical trial when possible
Thank you
5/5/2023 124

More Related Content

What's hot

JUNE 2023 ONCOLOGY CARTOONS
JUNE 2023 ONCOLOGY CARTOONSJUNE 2023 ONCOLOGY CARTOONS
JUNE 2023 ONCOLOGY CARTOONS
Kanhu Charan
 
DEBATE ON HIPPOCAMPAL SPARING IN WHOLE BRAIN RADIATION IN BRAIN METS
DEBATE ON HIPPOCAMPAL SPARING IN WHOLE BRAIN RADIATION IN BRAIN METSDEBATE ON HIPPOCAMPAL SPARING IN WHOLE BRAIN RADIATION IN BRAIN METS
DEBATE ON HIPPOCAMPAL SPARING IN WHOLE BRAIN RADIATION IN BRAIN METS
Kanhu Charan
 
Accelerated partial breast irradiation
Accelerated partial breast irradiationAccelerated partial breast irradiation
Accelerated partial breast irradiation
Bharti Devnani
 
PITUITARY ADENOMA RADIOTHERAPY PLANNING
PITUITARY ADENOMA RADIOTHERAPY PLANNINGPITUITARY ADENOMA RADIOTHERAPY PLANNING
PITUITARY ADENOMA RADIOTHERAPY PLANNING
Kanhu Charan
 
Craniospinal irradiation
Craniospinal irradiationCraniospinal irradiation
Craniospinal irradiation
Swarnita Sahu
 
AUGUST 2023 ONOLOGY CARTOONS
AUGUST 2023 ONOLOGY CARTOONSAUGUST 2023 ONOLOGY CARTOONS
AUGUST 2023 ONOLOGY CARTOONS
Kanhu Charan
 
Journal club TACE vs SBRT in Hepatocellular carcinoma
Journal club TACE vs SBRT in Hepatocellular carcinomaJournal club TACE vs SBRT in Hepatocellular carcinoma
Journal club TACE vs SBRT in Hepatocellular carcinoma
Anil Gupta
 
Management of Primary CNS Lymphoma (PCNSL)
Management of Primary CNS Lymphoma (PCNSL)Management of Primary CNS Lymphoma (PCNSL)
Management of Primary CNS Lymphoma (PCNSL)
Narayan Adhikari
 
Delineation of dysphagia aspiration related structures
Delineation of dysphagia aspiration related structuresDelineation of dysphagia aspiration related structures
Delineation of dysphagia aspiration related structures
Rajesh Balakrishnan
 
Prophylactic cranial irradiation
Prophylactic cranial irradiationProphylactic cranial irradiation
Prophylactic cranial irradiation
Shreya Singh
 
Role and Side effects of Ovarian Function Suppression in Breast Cancer
Role  and Side effects of Ovarian Function Suppression in Breast CancerRole  and Side effects of Ovarian Function Suppression in Breast Cancer
Role and Side effects of Ovarian Function Suppression in Breast CancerAjeet Gandhi
 
Liver sbrt
Liver sbrtLiver sbrt
Summary of embrace protocol
Summary of embrace protocolSummary of embrace protocol
Summary of embrace protocol
Dr. Ankita Pandey
 
Radioimmunotherapy
RadioimmunotherapyRadioimmunotherapy
Radioimmunotherapy
Aastha Shah
 
Hypofractionation in breast cancer
Hypofractionation in breast cancerHypofractionation in breast cancer
Hypofractionation in breast cancer
National Cancer Institute, AIIMS, New Delhi, India
 
MARCH 2023 ONCOLOGY CARTOONS
MARCH 2023 ONCOLOGY CARTOONSMARCH 2023 ONCOLOGY CARTOONS
MARCH 2023 ONCOLOGY CARTOONS
Kanhu Charan
 
Nasopharynx
Nasopharynx Nasopharynx
Nasopharynx
Swarnita Sahu
 
MANAGEMENT OF LOW GARDE GLIOMA
MANAGEMENT OF LOW GARDE GLIOMAMANAGEMENT OF LOW GARDE GLIOMA
MANAGEMENT OF LOW GARDE GLIOMA
Kanhu Charan
 
Hypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast CancerHypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast Cancer
Dr.Ram Madhavan
 

What's hot (20)

JUNE 2023 ONCOLOGY CARTOONS
JUNE 2023 ONCOLOGY CARTOONSJUNE 2023 ONCOLOGY CARTOONS
JUNE 2023 ONCOLOGY CARTOONS
 
DEBATE ON HIPPOCAMPAL SPARING IN WHOLE BRAIN RADIATION IN BRAIN METS
DEBATE ON HIPPOCAMPAL SPARING IN WHOLE BRAIN RADIATION IN BRAIN METSDEBATE ON HIPPOCAMPAL SPARING IN WHOLE BRAIN RADIATION IN BRAIN METS
DEBATE ON HIPPOCAMPAL SPARING IN WHOLE BRAIN RADIATION IN BRAIN METS
 
Accelerated partial breast irradiation
Accelerated partial breast irradiationAccelerated partial breast irradiation
Accelerated partial breast irradiation
 
PITUITARY ADENOMA RADIOTHERAPY PLANNING
PITUITARY ADENOMA RADIOTHERAPY PLANNINGPITUITARY ADENOMA RADIOTHERAPY PLANNING
PITUITARY ADENOMA RADIOTHERAPY PLANNING
 
Craniospinal irradiation
Craniospinal irradiationCraniospinal irradiation
Craniospinal irradiation
 
AUGUST 2023 ONOLOGY CARTOONS
AUGUST 2023 ONOLOGY CARTOONSAUGUST 2023 ONOLOGY CARTOONS
AUGUST 2023 ONOLOGY CARTOONS
 
Journal club TACE vs SBRT in Hepatocellular carcinoma
Journal club TACE vs SBRT in Hepatocellular carcinomaJournal club TACE vs SBRT in Hepatocellular carcinoma
Journal club TACE vs SBRT in Hepatocellular carcinoma
 
Management of Primary CNS Lymphoma (PCNSL)
Management of Primary CNS Lymphoma (PCNSL)Management of Primary CNS Lymphoma (PCNSL)
Management of Primary CNS Lymphoma (PCNSL)
 
Delineation of dysphagia aspiration related structures
Delineation of dysphagia aspiration related structuresDelineation of dysphagia aspiration related structures
Delineation of dysphagia aspiration related structures
 
Prophylactic cranial irradiation
Prophylactic cranial irradiationProphylactic cranial irradiation
Prophylactic cranial irradiation
 
Role and Side effects of Ovarian Function Suppression in Breast Cancer
Role  and Side effects of Ovarian Function Suppression in Breast CancerRole  and Side effects of Ovarian Function Suppression in Breast Cancer
Role and Side effects of Ovarian Function Suppression in Breast Cancer
 
Liver sbrt
Liver sbrtLiver sbrt
Liver sbrt
 
Summary of embrace protocol
Summary of embrace protocolSummary of embrace protocol
Summary of embrace protocol
 
Radioimmunotherapy
RadioimmunotherapyRadioimmunotherapy
Radioimmunotherapy
 
Hypofractionation in breast cancer
Hypofractionation in breast cancerHypofractionation in breast cancer
Hypofractionation in breast cancer
 
craniospinal irradiation
craniospinal irradiationcraniospinal irradiation
craniospinal irradiation
 
MARCH 2023 ONCOLOGY CARTOONS
MARCH 2023 ONCOLOGY CARTOONSMARCH 2023 ONCOLOGY CARTOONS
MARCH 2023 ONCOLOGY CARTOONS
 
Nasopharynx
Nasopharynx Nasopharynx
Nasopharynx
 
MANAGEMENT OF LOW GARDE GLIOMA
MANAGEMENT OF LOW GARDE GLIOMAMANAGEMENT OF LOW GARDE GLIOMA
MANAGEMENT OF LOW GARDE GLIOMA
 
Hypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast CancerHypofractionated Radiation Therapy in Breast Cancer
Hypofractionated Radiation Therapy in Breast Cancer
 

Similar to GLIOMA PANEL ISNOCON.pptx

HIGH GRADE GLIOMA MANAGEMENT
HIGH GRADE GLIOMA MANAGEMENTHIGH GRADE GLIOMA MANAGEMENT
HIGH GRADE GLIOMA MANAGEMENT
Nabeel Yahiya
 
Evolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumorsEvolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumors
Anil Gupta
 
Management of Low Grade Glioma
Management of Low Grade GliomaManagement of Low Grade Glioma
Management of Low Grade Glioma
Shreya Singh
 
JOURNAL CLUB CONFORMAL RT FOR PEDIATRIC LOW GRADE GLIOMA
JOURNAL CLUB CONFORMAL RT FOR PEDIATRIC LOW GRADE GLIOMAJOURNAL CLUB CONFORMAL RT FOR PEDIATRIC LOW GRADE GLIOMA
JOURNAL CLUB CONFORMAL RT FOR PEDIATRIC LOW GRADE GLIOMA
Faraz Badar
 
Pediatric cental nervous system tumors
Pediatric cental nervous system tumorsPediatric cental nervous system tumors
Pediatric cental nervous system tumors
Myatsu Aung
 
MANAGEMENT OF MENINGIOMA
MANAGEMENT OF MENINGIOMAMANAGEMENT OF MENINGIOMA
MANAGEMENT OF MENINGIOMA
Kanhu Charan
 
LUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEWLUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEW
Kanhu Charan
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
Rahul Wagh
 
CNS Medulloblastoma radiotherapy
CNS      Medulloblastoma     radiotherapyCNS      Medulloblastoma     radiotherapy
CNS Medulloblastoma radiotherapy
AjayBansal96
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.ppt
MusaibMushtaq
 
Low grade Glioma
Low grade Glioma Low grade Glioma
Low grade Glioma
Zeeshan Nasir
 
Evidence based management in High grade gliomas
Evidence based management in High grade gliomasEvidence based management in High grade gliomas
Evidence based management in High grade gliomas
Yamini Baviskar
 
Soft tissue sarcoma
Soft tissue sarcomaSoft tissue sarcoma
Soft tissue sarcoma
Silah Aysha
 
Central nervous system tumors in children
Central nervous system tumors in childrenCentral nervous system tumors in children
Central nervous system tumors in children
Sasikumar Sambasivam
 
LOW GRADE GLIOMA management in radiotherapy
LOW GRADE GLIOMA management in radiotherapyLOW GRADE GLIOMA management in radiotherapy
LOW GRADE GLIOMA management in radiotherapy
srinivasreddy200927
 
HYPOFRACTIONATION IN RADIOTHERAPY
HYPOFRACTIONATION IN RADIOTHERAPYHYPOFRACTIONATION IN RADIOTHERAPY
HYPOFRACTIONATION IN RADIOTHERAPY
Rejil Rajan
 
HYPOFRACTIONATION.pptx
HYPOFRACTIONATION.pptxHYPOFRACTIONATION.pptx
HYPOFRACTIONATION.pptx
DR REJIL RAJAN
 
Focussed therapy and imaging in prostate cancer
Focussed therapy and imaging in prostate cancerFocussed therapy and imaging in prostate cancer
Focussed therapy and imaging in prostate cancer
Prateek Laddha
 
14. Brain Tumour.pptx
14. Brain  Tumour.pptx14. Brain  Tumour.pptx
14. Brain Tumour.pptx
Ms.Elizabeth
 

Similar to GLIOMA PANEL ISNOCON.pptx (20)

HIGH GRADE GLIOMA MANAGEMENT
HIGH GRADE GLIOMA MANAGEMENTHIGH GRADE GLIOMA MANAGEMENT
HIGH GRADE GLIOMA MANAGEMENT
 
Evolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumorsEvolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumors
 
Management of Low Grade Glioma
Management of Low Grade GliomaManagement of Low Grade Glioma
Management of Low Grade Glioma
 
JOURNAL CLUB CONFORMAL RT FOR PEDIATRIC LOW GRADE GLIOMA
JOURNAL CLUB CONFORMAL RT FOR PEDIATRIC LOW GRADE GLIOMAJOURNAL CLUB CONFORMAL RT FOR PEDIATRIC LOW GRADE GLIOMA
JOURNAL CLUB CONFORMAL RT FOR PEDIATRIC LOW GRADE GLIOMA
 
Pediatric cental nervous system tumors
Pediatric cental nervous system tumorsPediatric cental nervous system tumors
Pediatric cental nervous system tumors
 
MANAGEMENT OF MENINGIOMA
MANAGEMENT OF MENINGIOMAMANAGEMENT OF MENINGIOMA
MANAGEMENT OF MENINGIOMA
 
LUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEWLUNG SBRT A LITERATURE REVIEW
LUNG SBRT A LITERATURE REVIEW
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 
CNS Medulloblastoma radiotherapy
CNS      Medulloblastoma     radiotherapyCNS      Medulloblastoma     radiotherapy
CNS Medulloblastoma radiotherapy
 
ca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.pptca prostate by Dr. Musaib Mushtaq.ppt
ca prostate by Dr. Musaib Mushtaq.ppt
 
Low grade Glioma
Low grade Glioma Low grade Glioma
Low grade Glioma
 
Evidence based management in High grade gliomas
Evidence based management in High grade gliomasEvidence based management in High grade gliomas
Evidence based management in High grade gliomas
 
Soft tissue sarcoma
Soft tissue sarcomaSoft tissue sarcoma
Soft tissue sarcoma
 
Central nervous system tumors in children
Central nervous system tumors in childrenCentral nervous system tumors in children
Central nervous system tumors in children
 
LOW GRADE GLIOMA management in radiotherapy
LOW GRADE GLIOMA management in radiotherapyLOW GRADE GLIOMA management in radiotherapy
LOW GRADE GLIOMA management in radiotherapy
 
HYPOFRACTIONATION IN RADIOTHERAPY
HYPOFRACTIONATION IN RADIOTHERAPYHYPOFRACTIONATION IN RADIOTHERAPY
HYPOFRACTIONATION IN RADIOTHERAPY
 
HYPOFRACTIONATION.pptx
HYPOFRACTIONATION.pptxHYPOFRACTIONATION.pptx
HYPOFRACTIONATION.pptx
 
GIST
GISTGIST
GIST
 
Focussed therapy and imaging in prostate cancer
Focussed therapy and imaging in prostate cancerFocussed therapy and imaging in prostate cancer
Focussed therapy and imaging in prostate cancer
 
14. Brain Tumour.pptx
14. Brain  Tumour.pptx14. Brain  Tumour.pptx
14. Brain Tumour.pptx
 

More from Kanhu Charan

ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
Kanhu Charan
 
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATROMOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
Kanhu Charan
 
MAY 2024 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
MAY 2024 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATROMAY 2024 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
MAY 2024 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
Kanhu Charan
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
Kanhu Charan
 
TARGET DELINEATION OF THORACIC NODAL. STATION
TARGET DELINEATION OF THORACIC NODAL. STATIONTARGET DELINEATION OF THORACIC NODAL. STATION
TARGET DELINEATION OF THORACIC NODAL. STATION
Kanhu Charan
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
Kanhu Charan
 
TARGET DELINEATION IN ANAL CANAL CANCER BY DR KANHU
TARGET DELINEATION IN ANAL CANAL CANCER BY DR KANHUTARGET DELINEATION IN ANAL CANAL CANCER BY DR KANHU
TARGET DELINEATION IN ANAL CANAL CANCER BY DR KANHU
Kanhu Charan
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
Kanhu Charan
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
Kanhu Charan
 
Oncology cartoons by Dr Kanhu Charan Patro
Oncology cartoons by Dr Kanhu Charan PatroOncology cartoons by Dr Kanhu Charan Patro
Oncology cartoons by Dr Kanhu Charan Patro
Kanhu Charan
 
RADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERRADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCER
Kanhu Charan
 
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUMEFEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
Kanhu Charan
 
Molecular Profile of Endometrial cancer.
Molecular Profile of Endometrial cancer.Molecular Profile of Endometrial cancer.
Molecular Profile of Endometrial cancer.
Kanhu Charan
 
ONCOLOGY CARTOONS JANUARY 2024 BY DR KANHU CHARAN PATRO
ONCOLOGY CARTOONS JANUARY 2024 BY DR KANHU CHARAN PATROONCOLOGY CARTOONS JANUARY 2024 BY DR KANHU CHARAN PATRO
ONCOLOGY CARTOONS JANUARY 2024 BY DR KANHU CHARAN PATRO
Kanhu Charan
 
TYPES OF STATISTICAL DATA BY DR KANHU CHARAN PATRO
TYPES OF STATISTICAL DATA  BY DR KANHU CHARAN PATROTYPES OF STATISTICAL DATA  BY DR KANHU CHARAN PATRO
TYPES OF STATISTICAL DATA BY DR KANHU CHARAN PATRO
Kanhu Charan
 
WHY STEREOTATXY IN CRANIAL AVM / DR KANHU CHARAN PATRO
WHY STEREOTATXY IN CRANIAL AVM / DR KANHU CHARAN PATROWHY STEREOTATXY IN CRANIAL AVM / DR KANHU CHARAN PATRO
WHY STEREOTATXY IN CRANIAL AVM / DR KANHU CHARAN PATRO
Kanhu Charan
 
PORTAL VEIN TUMOR THROMBOSIS SBRT/DR KANHU CHRAN PATRO
PORTAL VEIN TUMOR THROMBOSIS SBRT/DR KANHU CHRAN PATROPORTAL VEIN TUMOR THROMBOSIS SBRT/DR KANHU CHRAN PATRO
PORTAL VEIN TUMOR THROMBOSIS SBRT/DR KANHU CHRAN PATRO
Kanhu Charan
 
DR KANHU CHARTAN PATRO/ FOR ENT SURGEONS
DR KANHU CHARTAN PATRO/ FOR ENT SURGEONSDR KANHU CHARTAN PATRO/ FOR ENT SURGEONS
DR KANHU CHARTAN PATRO/ FOR ENT SURGEONS
Kanhu Charan
 
DECEMBER 2023 ONCOLOGY CARTOONS DRKANHU CHARAN PATRO
DECEMBER 2023 ONCOLOGY CARTOONS DRKANHU CHARAN PATRODECEMBER 2023 ONCOLOGY CARTOONS DRKANHU CHARAN PATRO
DECEMBER 2023 ONCOLOGY CARTOONS DRKANHU CHARAN PATRO
Kanhu Charan
 
DEBATE IN CA BLADDER TMT VS CYSTECTOMY
DEBATE IN CA BLADDER TMT VS CYSTECTOMYDEBATE IN CA BLADDER TMT VS CYSTECTOMY
DEBATE IN CA BLADDER TMT VS CYSTECTOMY
Kanhu Charan
 

More from Kanhu Charan (20)

ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
 
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATROMOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
 
MAY 2024 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
MAY 2024 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATROMAY 2024 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
MAY 2024 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
TARGET DELINEATION OF THORACIC NODAL. STATION
TARGET DELINEATION OF THORACIC NODAL. STATIONTARGET DELINEATION OF THORACIC NODAL. STATION
TARGET DELINEATION OF THORACIC NODAL. STATION
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
 
TARGET DELINEATION IN ANAL CANAL CANCER BY DR KANHU
TARGET DELINEATION IN ANAL CANAL CANCER BY DR KANHUTARGET DELINEATION IN ANAL CANAL CANCER BY DR KANHU
TARGET DELINEATION IN ANAL CANAL CANCER BY DR KANHU
 
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHUTARGET DELINEATION IN VULVAL CANCER BY DR KANHU
TARGET DELINEATION IN VULVAL CANCER BY DR KANHU
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
 
Oncology cartoons by Dr Kanhu Charan Patro
Oncology cartoons by Dr Kanhu Charan PatroOncology cartoons by Dr Kanhu Charan Patro
Oncology cartoons by Dr Kanhu Charan Patro
 
RADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCERRADIATION THERAPY IN BILIARY TRACT CANCER
RADIATION THERAPY IN BILIARY TRACT CANCER
 
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUMEFEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
FEBRUARY 2024 ONCOLOGY CARTOON /95TH VOLUME
 
Molecular Profile of Endometrial cancer.
Molecular Profile of Endometrial cancer.Molecular Profile of Endometrial cancer.
Molecular Profile of Endometrial cancer.
 
ONCOLOGY CARTOONS JANUARY 2024 BY DR KANHU CHARAN PATRO
ONCOLOGY CARTOONS JANUARY 2024 BY DR KANHU CHARAN PATROONCOLOGY CARTOONS JANUARY 2024 BY DR KANHU CHARAN PATRO
ONCOLOGY CARTOONS JANUARY 2024 BY DR KANHU CHARAN PATRO
 
TYPES OF STATISTICAL DATA BY DR KANHU CHARAN PATRO
TYPES OF STATISTICAL DATA  BY DR KANHU CHARAN PATROTYPES OF STATISTICAL DATA  BY DR KANHU CHARAN PATRO
TYPES OF STATISTICAL DATA BY DR KANHU CHARAN PATRO
 
WHY STEREOTATXY IN CRANIAL AVM / DR KANHU CHARAN PATRO
WHY STEREOTATXY IN CRANIAL AVM / DR KANHU CHARAN PATROWHY STEREOTATXY IN CRANIAL AVM / DR KANHU CHARAN PATRO
WHY STEREOTATXY IN CRANIAL AVM / DR KANHU CHARAN PATRO
 
PORTAL VEIN TUMOR THROMBOSIS SBRT/DR KANHU CHRAN PATRO
PORTAL VEIN TUMOR THROMBOSIS SBRT/DR KANHU CHRAN PATROPORTAL VEIN TUMOR THROMBOSIS SBRT/DR KANHU CHRAN PATRO
PORTAL VEIN TUMOR THROMBOSIS SBRT/DR KANHU CHRAN PATRO
 
DR KANHU CHARTAN PATRO/ FOR ENT SURGEONS
DR KANHU CHARTAN PATRO/ FOR ENT SURGEONSDR KANHU CHARTAN PATRO/ FOR ENT SURGEONS
DR KANHU CHARTAN PATRO/ FOR ENT SURGEONS
 
DECEMBER 2023 ONCOLOGY CARTOONS DRKANHU CHARAN PATRO
DECEMBER 2023 ONCOLOGY CARTOONS DRKANHU CHARAN PATRODECEMBER 2023 ONCOLOGY CARTOONS DRKANHU CHARAN PATRO
DECEMBER 2023 ONCOLOGY CARTOONS DRKANHU CHARAN PATRO
 
DEBATE IN CA BLADDER TMT VS CYSTECTOMY
DEBATE IN CA BLADDER TMT VS CYSTECTOMYDEBATE IN CA BLADDER TMT VS CYSTECTOMY
DEBATE IN CA BLADDER TMT VS CYSTECTOMY
 

Recently uploaded

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
DR SETH JOTHAM
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 

GLIOMA PANEL ISNOCON.pptx

  • 1. LOW GRADE GLIOMA PANEL 5/5/2023 1 DR L N TRIPATHY Senior Vice Chairman, Director Senior Consultant, Neurosurgery Medica Super specialty Hospital, Kolkata ISNOCON 2023- KOLKATA DR KANHU CHARAN PATRO HOD, Radiation Oncology Mahatma Gandhi Cancer Hospital & RI Visakhapatnam
  • 8.
  • 9.
  • 10.
  • 11. Definition The term diffuse infiltrating means there is no identifiable border between the tumour and normal brain tissue, even though the borders may appear well-marginated on imaging 5/5/2023 11
  • 12. Some facts • Diffuse astrocytomas, also referred to as low-grade infiltrative astrocytomas, are designated as WHO II tumours of the brain. • Commonly, astrocytomas are confined to white matter although they can infiltrate and expand the adjacent cortex in later stages. • However, oligodendroglioma is frequently a cortical-based tumor. • Although contrast enhancement has been classically associated with a higher degree of malignancy, contrast enhancement may be seen in up to 20% of LGG 5/5/2023 12
  • 13. Case details 39-year male • P/w –frontal headache • Personality changes- 6 month • Single episode of generalized seizure • Disturbance with selective attention MRI • LT. temporal lesion • 6cm in greatest dimension • Solid cystic pattern • No enhancement • Midline shift • Mass effect • Ventricular effacement
  • 15. RADIOLOGY • PRESCRIPTION • MRS,DIFFUSION,PERFUSION • TRACTOGRAPHY • RADIOMICS AND RADIOGENOMICS
  • 16. T1
  • 18. T2
  • 22. SWI
  • 24. MRS
  • 26. 2HG MRS 5/5/2023 26 IDH MUTATION IDH WILD using 2 mM 2HG as threshold to discriminate IDH-mutated from wildtype tumors
  • 31. NEUROSURGERY • What type surgery • Eloquent location • Stereotactic biopsy • Imaging after surgery • Awake craniotomy
  • 32. Surgery recommendation • It is assumed that surgery should aim for the greater extent of resection as it would Increase survival and potentially alter the natural history of the disease: gross total removal or subtotal tumor removal (when feasible and safe) is superior to biopsy in terms of decreasing the rate of tumor progression and also have positive impact in overall survival estimation of resection less than 50% would lead to consider biopsy. • A retrospective multicentric study analyzing 1097 patients (in which the assessed population was divided into three subgroups depending on the extent of resection: 100%, 50–99% and less than 50%) showed that the amount of residual lesion impacted on the course of the disease (OS was 10.5 and 14 years for patients with a less than 50 and 50–99% Extent of resection, being unreached instead after 15 years for patients with no residual tumor). • Biopsy is indicated when diagnosis is needed in deep lesions (including brainstem), diffuse and/or multicentric tumor or any other contraindication for open resection. • Biopsy can be stereotactic (framed or frameless) or open. Neuronavigated non-framed biopsy is gaining acceptance. 5/5/2023 32
  • 33. SURGERY • PATIENT UNDERWENT SURGERY • COMPLETE EXCISION • BETTER AFTER SURGERY 5/5/2023 33
  • 34. Dr ADHITHYAN PLEASE POST OP IMAGING PROTOCOL
  • 35. TIMING OF POST OP MRI 5/5/2023 35
  • 40. Brain tumor diagnosis Next generation sequence [NGS] Methylation profiling Immunohistochemistry [IHC] Microscopic Histology 40
  • 41. Layered reporting in brain tumors Thus, to display the full range of diagnostic information available, the use of layered (or tiered) diagnostic reports is strongly encouraged, as endorsed by the International Society of Neuropathology—Haarlem consensus guidelines and the International Collaboration on Cancer Reporting.
  • 43. H/ P REPORT • DIFFUSE GLIOMA • GRADE ll 5/5/2023 43 1. Nuclear irregularities with fibrillary processes are diagnosed as astrocytoma 2. Infiltrative, diffuse growth pattern with the formation of secondary structures of Scherer Moderately cellular 3. Irregular cell distribution 4. Nuclear atypia is typical, yet variable: enlarged elongated hyperchromatic irregular nuclei 5. Variable amount of cytoplasm: may be scant (naked nuclei) to moderate with processes creating a fibrillary background 6. No mitotic activity (a single mitosis in a sizable specimen is allowed) 7. No necrosis or microvascular proliferation 8. Variable microcystic change 9. Variable calcification
  • 44. Oligodendroglioma 5/5/2023 44 Micrograph of an oligodendroglioma showing the characteristic branching, small, chicken wire-like blood vessels and fried egg-like cells, with clear cytoplasm and well-defined cell borders. H&E stain. Those with uniformly rounded nuclei and perinuclear halo (‘‘fried egg’’) are considered oligodendrogliomas.
  • 46. Defining and grading of IDH mutant and IDH wild 46
  • 47.
  • 48. Adult diffuse gliomas – current status
  • 50. IDH MUTATION AND GLIOMA-GENESIS 5/5/2023 50
  • 52. Diffuse glioma Oligodendro glioma IDH mutant 1p19q co-deleted Glioblastoma IDH wild Diffuse glioma IDH mutant 52
  • 53. Diffuse glioma Oligodendro glioma IDH mutant 1p19q co-deleted IDH wild Glioblastoma Diffuse glioma IDH mutant 53 Grade-2 Grade-3 Grade-4 Grade-2 Grade-3
  • 54.
  • 55. When will we call as glioblastoma? • Diffuse astrocytoma IDH wild type with • TERT promoter mutation • Necrosis • Microvascular proliferation • EGFR gene amplification • Combined entire gain of chromosome 7 and entire loss of chromosome 10[+7/-10] 55
  • 56. Revised schema of classification: post WHO CNS5
  • 58. FINAL REPORT • DIFFUSE GLIOMA • IDH MUTANT • 1P/19q CO DELETION • OLIGODENDDROGLIOMA • GRADE ll
  • 61.
  • 62.
  • 64. Options • RT alone • RT- adj. PCV • RT- adj. TMZ • RT- conc. And adj. TMZ - 6 • RT- conc. And adj. TMZ - 12 5/5/2023 64
  • 65. Planning for observation • Besides IDH wild-type status, other high-risk factors include – Age > 40 years, – Subtotal resection/biopsy only, – Astrocytic lineage (lack of 1p/19q codeletion), – Neurologic deficits prior to surgery, – Tumor diameter > 6 cm, tumor crossing the midline of the brain, – tumors located within or adjacent to eloquent areas of the brain • Patients without these risk factors can be considered at low risk; therefore, after gross total resection, they should be observed closely with surveillance MRI every 3 months initially, and if there is no demonstrated tumor growth over a 1-year period, then the imaging interval can be increased to every 4 months for another year, and eventually every 6 months for the remainder of the patient’s life 5/5/2023 65
  • 66.
  • 68. DR VIKAS PLEASE DOSE AND TECHNIQUE
  • 72. GTV- CTV- PTV PARAMETERS
  • 73.
  • 74.
  • 78. DR DEVLEENA PLEASE ABOUT CONC. AND ADJUVANT CHEMO
  • 81. Concurrent CTRT trial 5/5/2023 81 TRIAL INCLUSION ARM RESULT RTOG 0424 LGG with >3 risk factors for recurrence (age > 40 years, astrocytoma histology, bihemispheric tumor, tumor diameter[6 cm, neurologic function status Concurrent radiation (54 Gy) with TMZ f/b monthly TMZ 1. The 3-year OS rate was 73% (95% CI 65.3–80.8%), significantly higher than the historical control OS rate of 54% (p0.001). 2. The 5-year OS rate was 57.1% (95% CI 47.7–66.5%), and the median OS has not yet been reached. 3. The 3-year PFS was 59.2% (95% CI 50.7–67.8%) and median PFS was 4.5 years (95% CI 3.5–NA). Fisher BJ. J Radiat Oncol Biol Phys.(2015)
  • 82. For anaplastic astrocytoma IDHmt, the interim results of the CATNON trials strongly suggest treatment with 59.4Gy radiotherapy in fractions of 1.8Gy followed by 12 cycles of adjuvant temozolomide chemotherapy (200mg/m2 days 1–5 in a 4-week cycle
  • 83. CODEL
  • 84.
  • 85. Adjuvant chemo • After radiation, patient received adjuvant PCV (procarbazine, CCNU, and vincristine) due to 1p/19q co-deletion (per RTOG 9802).
  • 86. PCV trial 5/5/2023 86 TRIAL INCLUSION ARM RESULT RTOG 9802 1. Age >40 years and/or subtotal resection RT (54 Gy) VS RT (54 Gy) And 6 cycles of adjuvant PCV 1. Post-RT + PCV conferring a survival advantage over RT alone: median OS 13.3 versus 7.8 years (HR: 0.59; 95% CI 0.42–0.83; p = 0.003). 2. Median PFS was prolonged in patients who received PCV (10.4 versus 4.0 years): HR: 0.50; 95% CI 0.36–0.68 (p0.001) Buckner JC. N Engl J Med(2016)
  • 88.
  • 90. Radiotherapy trials 5/5/2023 90 TRIAL INCLUSION ARM RESULT EORTC 22844 1. Low-grade astrocytomas Low dose RT (45 Gy) VS High dose RT (59.4 Gy) 1. No significant difference in the 5- years OS between low-dose arm (58%) and high dose arm (59%). 2. No significant difference in the 5- years PFS (47% verss 50%) Karim AB. Int J Radiat Oncol Biol Phys 1996
  • 91. Radiotherapy trials 5/5/2023 91 TRIAL INCLUSION ARM RESULT EORTC 22845 Interim 1. Low-grade astrocytoma Early RT (54 Gy) VS No RT 1. Early RT showed an improvement in TTP (4.8 versus 3.4 years; p = 0.02). HR = 0.68 (95% CI 0.50–0.94). 2. No differences in OS: HR = 1.15 (95% CI 0.67–1.74). 3. The 5-year OS rate were: 63 versus 66% (p = 0.49). (Karim AB. Int J Radiat Oncol Biol Phys(2002)
  • 92. Radiotherapy trials 5/5/2023 92 TRIAL INCLUSION ARM RESULT EORTC 22845 1. WHO grade II RT (54 Gy) after biopsy resection, VS No RT until progression 1. Early RT was associated with an improvement PFS (5.3 versus 3.4 years): HR = 0.59; 95% CI 0.45–0.77 (p = 0.0001). 2. No difference in OS (7.4 versus 7.2 years): HR = 0.97; 95% CI 0.71–1.34 8 (p = 0.872) 3. Seizure control also improved in patients treated with early radiotherapy. Van den Bent MJ. Lancet 2005)
  • 93. Radiotherapy trials 5/5/2023 93 TRIAL INCLUSION ARM RESULT NCCTG/RTOG/ ECOG 1. WHO grade II gliomas Low dose RT (50.4 Gy) VS High dose RT (64.8 Gy) 1. No differences in 2- and 5-year OS between low dose (94 and 75%) and high dose arm (85 and 64%) (p = 0.48) 2. Patients treated with high doses showed higher rates of severe radionecrosis (5 versus 2.5%) Shaw EG. J Clin Oncol. (2002)
  • 94. Radiotherapy trials 5/5/2023 94 TRIAL INCLUSION ARM RESULT RTOG 0424 LGG with >3 risk factors for recurrence (age > 40 years, astrocytoma histology, bihemispheric tumor, tumor diameter[6 cm, neurologic function status Concurrent radiation (54 Gy) with TMZ f/b monthly TMZ 1. The 3-year OS rate was 73% (95% CI 65.3–80.8%), significantly higher than the historical control OS rate of 54% (p0.001). 2. The 5-year OS rate was 57.1% (95% CI 47.7–66.5%), and the median OS has not yet been reached. 3. The 3-year PFS was 59.2% (95% CI 50.7–67.8%) and median PFS was 4.5 years (95% CI 3.5–NA). Fisher BJ. J Radiat Oncol Biol
  • 95. Radiotherapy trials 5/5/2023 95 TRIAL INCLUSION ARM RESULT EORTC 22033 LGG with at least one high-risk feature (aged>40 years, progressive disease, tumour Size>5 cm, tumour crossing the midline, or neurological symptoms) RT ( 50.4 Gy VERSUS Dose-dense oral TMZ (75 mg/m2 once daily for 21 days, every 28 days, for a maximum of 12 cycles) 1. There was no significant difference in PFS between TMZ group (39 months) and RT group (46 months): HR: 1.16; 95% CI 0.9–1.5 (p = 0.22). 2. Median OS has not been reached. 3. Better PFS in IDH-mutant noncodeleted patients treated with radiotherapy: 55 versus 36 months. HR 1.86; 95% CI 1.21–2.87 (p = 0.0043) Baumert BG Lancet Oncol.
  • 96. Radiotherapy trials 5/5/2023 96 TRIAL INCLUSION ARM RESULT Wahl M,et al LGG and gross residual disease Monthly cycles of TMZ for up to 1 year or until disease progression 1. The median PFS and OS were 4.2 and 9.7 years, respectively. 2. Patients with 1p/19q codeletion demonstrated a 0% risk of progression during treatment Neuro Oncol.(2017)
  • 97. Recommendation -1 • People with oligodendroglioma, IDH-mutant, 1p19q codeleted, CNS WHO grade 2 should be offered radiation in combination with PCV • TMZ is a reasonable alternative to PCV when toxicity is a concern 5/5/2023 97
  • 98.
  • 99. Recommendation -2 • People with oligodendroglioma, IDH-mutant, 1p19q codeleted, CNS WHO grade 2, initial therapy may be deferred until radiographic or symptomatic progression in some people with positive prognostic factors (eg, complete resection and younger age) or concerns about toxicity
  • 100. Recommendation -3 • People with oligodendroglioma, IDH-mutant, 1p19q codeleted, CNS WHO grade 3 should be offered radiation in combination with PCV • TMZ is a reasonable alternative to PCV when toxicity is a concern
  • 101. GRADE 3 IDH MUTANT AND CODELETED TUMORS
  • 102. Recommendation -4 • People with Astrocyoma, IDH-mutant, 1p19q NONcodeleted, CNS WHO grade 2 should be offered radiation in combination with PCV • TMZ is a reasonable alternative to PCV when toxicity is a concern GRADE 2 IDH MUTANT AND NON-CODELETED TUMORS
  • 103.
  • 104. Recommendation -5 • People with Astrocytoma, IDH-mutant, 1p19q NONcodeleted, CNS WHO grade 2, initial therapy may be deferred until radiographic or symptomatic progression in some people with positive prognostic factors (eg, complete resection and younger age) or concerns about toxicity
  • 105.
  • 106. Recommendation -6 • People with astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 3 should be offered RT with adjuvant TMZ
  • 107.
  • 108. Recommendation -7 • People with astrocytoma, IDH mutant CNS WHO grade 4 may be treated like an astrocytoma, IDH-mutant, non-codeleted, CNS WHO grade 3 (formerly anaplastic astrocytoma; see Recommendation 6) or like a glioblastoma, IDH-wildtype, CNS WHO grade 4
  • 109. Recommendation - 8 • People with astrocytomas, IDH-wildtype, CNS WHO grade 2 or 3 may be treated according to recommendations for glioblastoma
  • 110. Recommendation -9 • Concurrent TMZ and RT should be offered to people with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4
  • 111. Recommendation -10 • Six months of adjuvant TMZ should be offered to people with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4 who have received concurrent RT plus TMZ
  • 112.
  • 113. Recommendation -11 • Alternating electric field therapy may be added to adjuvant TMZ in people with newly diagnosed supratentorial glioblastoma, IDH-wildtype, CNS WHO grade 4 who have completed chemoradiation therapy
  • 114.
  • 115. Recommendation -12 • Bevacizumab is not recommended for people with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4
  • 116. Bevacizumab is not recommended for people with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4 Benefits do not outweigh harms
  • 117. Recommendation -13 • In people with glioblastoma, IDH-wildtype, CNS WHO grade 4 where the expected survival benefits of a 6-week radiation course combined with TMZ may not outweigh the harms, hypofractionated RT combined with TMZ is a reasonable alternative
  • 118.
  • 119. Recommendation -14 • In people with glioblastoma, IDH-wildtype, CNSWHO grade 4 with older age, poor performance status or with concerns about toxicity or prognosis, best supportive care alone, hypofractionated RT alone (for MGMT promoter unmethylated tumors) or TMZ alone (for MGMT promoter methylated tumors) are reasonable options.
  • 120.
  • 121. Recommendation -15 • No recommendation for or against any therapeutic strategy can be made for treatment of recurrent glioblastoma, IDH wildtype, CNS WHO grade 4 • People with recurrent glioblastoma should be referred for participation in a clinical trial where possible
  • 122. Recommendation -16 • No recommendation for or against any therapeutic strategy can be made for treatment of diffuse midline glioma • People with diffuse midline glioma should be referred for participation in a clinical trial when possible
  • 123.